<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474900</article-id><article-id pub-id-type="pmcid-ver">PMC12474900.1</article-id><article-id pub-id-type="pmcaid">12474900</article-id><article-id pub-id-type="pmcaiid">12474900</article-id><article-id pub-id-type="pmid">41006573</article-id><article-id pub-id-type="doi">10.1038/s41598-025-17982-3</article-id><article-id pub-id-type="publisher-id">17982</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Discovery of novel disulfide-containing PD-1/PD-L1 inhibitor with in vivo influenza therapeutic efficacy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hirata</surname><given-names initials="Y">Yoshiyuki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayashi</surname><given-names initials="K">Kyoko</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kato</surname><given-names initials="T">Takuma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nagaoka</surname><given-names initials="Y">Yasuo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doi</surname><given-names initials="M">Mitsunobu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Uesato</surname><given-names initials="S">Shinichi</given-names></name><address><email>shinichi.uesato@ompu.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01y2kdt21</institution-id><institution-id institution-id-type="GRID">grid.444883.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2109 9431</institution-id><institution>Faculty of Pharmacy, </institution><institution>Osaka Medical and Pharmaceutical University, </institution></institution-wrap>Takatsuki, Osaka Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02sps0775</institution-id><institution-id institution-id-type="GRID">grid.254217.7</institution-id><institution-id institution-id-type="ISNI">0000 0000 8868 2202</institution-id><institution>College of Life and Health Sciences, </institution><institution>Chubu University, </institution></institution-wrap>Kasugai, Aichi Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03xg1f311</institution-id><institution-id institution-id-type="GRID">grid.412013.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2185 3035</institution-id><institution>Faculty of Chemistry, Materials and Bioengineering, </institution><institution>Kansai University, </institution></institution-wrap>Suita, Osaka Japan </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>32998</elocation-id><history><date date-type="received"><day>9</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 15:25:44.047"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_17982.pdf"/><abstract id="Abs1"><p id="Par1">Monoclonal antibody-based immune checkpoint inhibitors, which have brought breakthrough effects in cancer treatments, are expected to assist in the treatment of viral diseases. However, antibody therapies may cause immune-related side effects, such as inflammation and pneumonia, due to cytokine storms. Small-molecule PD-1/PD-L1 inhibitors are an alternative to monoclonal antibody-based therapeutics. We have identified a novel small-molecule PD-1/PD-L1 inhibitor having a functional group (disulfide group), namely compound <bold>2</bold> (molecular weight: 456.6), from our library of sulfur-containing protein&#8211;protein interaction inhibitor compounds. Compound <bold>2</bold> selectively bound to PD-L1 over PD-1, with the dissociation rate constant (K<sub>D</sub>) of 77.60&#8201;&#177;&#8201;4.44&#160;nM (obtained by affinity analysis) and showed promising T cell activation recovery. A molecular docking simulation study between <bold>2</bold> and PD-L1 suggested that <bold>2</bold> binds to PD-L1 in a binding mode different from those of other small-molecule PD-L1/PD-1 inhibitors. Notably, oral administration of <bold>2</bold> to mice pre-infected with influenza A virus (A/NWS/33, H1N1 subtype) caused a significant increase in the neutralizing antibody titers, as well as recovery from influenza-induced pneumonia. Overall, <bold>2</bold> provides insight for the development of therapeutic drugs against early viral infections, with both virus titer-reducing and antibody titer-boosting effects. Moreover, <bold>2</bold> is widely used as a rubber peptizing agent in the production process of tires and other rubber products. Our findings may provide useful information for investigating its influence on living organisms.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-17982-3.</p></sec></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Drug discovery and development</kwd><kwd>Pharmacology</kwd><kwd>Screening</kwd><kwd>Structure-based drug design</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">
Antagonistic substances against immune checkpoint proteins, such as programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), were initially developed as anticancer treatments because cancers exploit these proteins to evade detection by the immune system. To date, eight monoclonal antibodies (anti-PD-1 antibodies: nivolumab, pembrolizumab, and cemiplimab; anti-PD-L1 antibodies: atezolizumab, avelumab, and durvalumab; anti-CTLA4 antibodies: ipilimumab and tremelimumab) have been approved by the U.S. Food and Drug Administration<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref></sup>. Additionally, as next-generation immune checkpoint inhibitors, the antibodies against lymphocyte activation gene 3 (LAG-3), T cell immunoglobulin and mucin-domain-containing-3 (TIM-3), and T cell immunoreceptor with Ig and ITIM domains (TIGIT) are under pre-clinical or clinical trials<sup><xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref></sup>. These antibodies have been exclusively applied to cancer treatments, and further applications are anticipated against viral infectious diseases such as influenza<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, progressive multifocal leukoencephalopathy<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, human immunodeficiency virus disease<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>, and hepatitis B and hepatitis C<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. However, the antibody therapies can sometimes cause immune-related adverse effects, including inflammation or pneumonia, due to cytokine storm<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Furthermore, several problems persist: high production costs, a lack of oral administration, a short half-life, and poor penetration in organs and tumors. Therefore, the development of low-molecular-weight compounds that antagonize the immune checkpoint proteins is warranted. Bristol-Myers Squibb (BMS) has designed numerous nonpeptidic small molecular PD-1/PD-L1 inhibitors<sup><xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref></sup>. They successfully synthesized two types of inhibitors: (2-methyl-3-biphenylyl)methanol derivatives and [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol derivatives. X-ray diffraction analyses revealed that these derivatives bound to the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 molecules. Additionally, the two optimized BMS compounds, BMS-1001 and BMS-1166, bound to human PD-L1, induced PD-L1 protein dimerization, and blocked its interaction with human PD-1<sup><xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref></sup>. Various other small-molecule immune checkpoint inhibitors have been reported<sup><xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref></sup>. Recently, CA-170<sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup>, a dual inhibitor of PD-L1 and VISTA, has reached Phase 2b/3 clinical trials. This compound blocks PD-L1 signaling without preventing the assembly of the PD-1/PD-L1 complex and shows anti-tumor efficacy. Moreover, clinical trials are currently ongoing to the anticancer potency of the PD-L1-specific inhibitors GS 4224, INCB086550, and IMMH-010<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>.</p><p id="Par3">We previously hypothesized that some thiol- or disulfide-containing compounds can disrupt protein&#8211;protein interactions (PPIs) by binding to the cysteine-cysteine disulfide or cysteine-thiol of proteins, respectively, <italic toggle="yes">via</italic> thiol-disulfide exchange reactions, potentially allowing for the separation of bound proteins. Based on this hypothesis, we designed a series of sulfur-containing compounds to screen for Murine double minute 4 (Mdmx) inhibitors, and ultimately identified K-178 (<bold>8</bold>), which selectively inhibited the binding of p53 with Mdmx over the binding of p53 with other partners, including Murine double minute 2 (Mdm2)[&#160;32&#160;].</p><p id="Par4">In this study, we searched for new PD-1/PD-L1 binding inhibitors from our library of sulfur-based and related compounds, aiming to perform oral administration experiments using mice pre-infected with influenza virus (IFV). The screening for PD-1/PD-L1 inhibitors by ELISA led to the identification of 2-benzamido diphenyl disulfide (<bold>2</bold>), which inhibited the PD-1/PD-L1 interaction with an IC<sub>50</sub> of 5.7&#8211;6.2&#160;nM (Sect.&#160;1 in Supplementary Information), comparable to the reported IC<sub>50</sub> (6&#8211;100&#160;nM) of the positive control, BMS-1&#160;<sup><xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref></sup>. The surface plasmon resonance (SPR) analysis confirmed that compound <bold>2</bold> selectively bound to PD-L1 over PD-1 with an equilibrium dissociation rate constant (K<sub>D</sub>) of 77.60&#8201;&#177;&#8201;4.44&#160;nM. Furthermore, the T cell activation recovery assay suggested that <bold>2</bold> has a T cell-activating effect similar to that of CA-170. Notably, <bold>2</bold> showed promising therapeutic effect after oral administration to mice that were intranasally pre-infected with IFV (A/NWS/33, H1N1 subtype) and increased the neutralizing antibody titers. These results suggest that <bold>2</bold> represents a new drug candidate for viral infections with both virus titer-reducing and antibody titer-enhancing effects.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Identification of new type of PD-1/PD-L1 inhibitor 2 by ELISA analysis</title><p id="Par5">
For the first screening, we assessed the inhibition effect of the dimeric disulfide compounds (<bold>1</bold>, <bold>2</bold>, <bold>3</bold>, <bold>4a</bold>&#8211;<bold>e</bold>, and <bold>5</bold>) and the monomeric sulfur-containing compounds (<bold>6</bold>, <bold>7</bold>, <bold>8</bold>, <bold>9</bold>, and <bold>10</bold>), together with BMS-1 (positive control) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A), on the PD-1/PD-L1 interaction by ELISA. We incubated the test compounds (all at 10&#160;&#956;M) with the biotinylated PD-1 Fc Chimera (0.25&#160;&#956;M) on a Ni-coated plate with immobilized His-tagged PD-L1 (0.25&#160;&#956;M). Then, we successively treated the plates with horseradish-peroxidase (HRP)-bound streptavidin and the coloring agent tetramethylbenzidine (TMB), as indicated in the experimental Sect. &#8220;<xref rid="Sec9" ref-type="sec">Methods</xref>&#8221;. We calculated the proportion of PD-1-bound PD-L1 by dividing the absorbance at 450&#160;nm of the wells containing test compounds by the absorbance of wells containing no test compound (control). As shown in Figs.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B, compound&#160;<bold>2</bold>&#160;and BMS-1 inhibited 76% and 58% of the PD-1/PD-L1 binding, respectively. Meanwhile, <bold>4a</bold>, <bold>3</bold>, and <bold>8</bold> inhibited 34%, 34%, and 39% of the PD1/PD-L1 binding, respectively, and the pyridinyl ring-possessing compounds <bold>4b</bold>&#8211;<bold>d</bold> and the meta-isomer of <bold>2</bold> (<bold>5</bold>) barely inhibited the interaction. Although the monomeric sulfide derivative of <bold>2</bold> (<bold>6</bold>) reduced binding by 21%, this value fluctuated with each measurement (data not shown). We speculate that <bold>6</bold> was partially converted into the dimer <bold>2</bold> by air oxidation during incubation, which may have contributed to the protein&#8211;protein binding inhibition. Next, to investigate the structure&#8211;activity relationship, we compared the inhibition efficacies of <bold>2</bold> and <bold>6</bold> with the meta- and para-isomers of <bold>2</bold> (<bold>5</bold> and <bold>11</bold>), <bold>6</bold> (<bold>12</bold> and <bold>13</bold>), and <bold>8</bold> (<bold>14</bold> and <bold>15</bold>), as well as with CH<sub>2</sub>-O bioisostere (<bold>16</bold>) and oxygen-substituted compounds <bold>17</bold> and <bold>18</bold> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Screening of sulfur-containing compounds for the inhibition of PD-1/PD-L1 interaction by ELISA. (<bold>A</bold>) Test compounds. (<bold>B</bold>) First screening results. (<bold>C</bold>) Second screening results. Each value is the mean&#8201;&#177;&#8201;standard error of the mean from triplicate measurements. *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 <italic toggle="yes">versus</italic> the control (0.1% DMSO). The experiments were repeated more than three times to ensure reliability.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2025_17982_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Characterization of the PD-1/PDL1 interaction inhibitors by SPR. (<bold>A</bold>) Representative sensorgram of PD-1 on immobilized PD-L1. (<bold>B</bold>) Representative sensorgrams of PD-1 on immobilized PD-L1 in the presence or absence of tested compounds. As a control, 1% DMSO was used. (<bold>C</bold>) Representative sensorgrams of <bold>2</bold> on immobilized PD-L1 or PD-1. (<bold>D</bold>) The fitting curve of the response measured at equilibrium plotted against the compound <bold>2</bold> concentration. All experiments were repeated more than three times to ensure reliability.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41598_2025_17982_Fig2_HTML.jpg"/></fig></p><p id="Par6">As shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C, except for BMS-1 and compound <bold>2</bold>, none of the test compounds exhibited noticeable inhibitory activity. Thus, compound <bold>2</bold> has a PD-1/PD-L1 inhibitory activity similar to that of BMS-1.</p></sec><sec id="Sec4"><title>Determination of the binding preference of compound 2 to PD-L1 over PD-1 by surface plasmon resonance (SPR)</title><p id="Par7">
Subsequently, we performed SPR to confirm the above results<sup><xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref></sup>. First, we conducted the PD-L1/PD-1 binding assay using His-tagged PD-L1 as a ligand and PD-1 Fc Chimera as an analyte. We immobilized His-tagged PD-L1 (1.0&#160;&#956;M) on a Biacore Sensor Chip CM5. Then, we injected the PD-1 Fc Chimera (0.001, 0.125, 0.25, 0.5, and 1.0&#160;&#956;M) over the immobilized PD-L1. As shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A, the resonance unit (RU) decreased with decreasing concentrations of PD-1. Second, we pre-mixed the test compounds (0.1 or 0.01&#160;&#956;M) with the PD-1 Fc Chimera (0.1&#160;&#956;M) and injected them over the immobilized His-tagged PD-L1 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). BMS-1 and <bold>2</bold> (both 0.01&#160;&#956;M) decreased the experimental maximum binding responses (Rmax) to 56% and 71% of the control value (Rmax&#8201;=&#8201;1090&#160;RU), respectively. Increasing the concentration of BMS-1 and <bold>2</bold> from 0.01 to 0.1&#160;&#956;M decreased the Rmax values to 40% and 50% of the control, respectively. These results suggest that <bold>2</bold> inhibited the PD-L1/PD-1 binding at similar levels to BMS-1. Third, we investigated whether compound <bold>2</bold> bound to either PD-L1 or PD-1. We injected His-tagged PD-L1 (1.0&#160;&#956;M) or PD-1 Fc Chimera (1.0&#160;&#956;M) on a Biacore Sensor Chip CM5 to immobilize them. Then, we injected <bold>2</bold> (0.01, 0.1, 0.5, or 1.0&#160;&#956;M) through a ligand cell (immobilized His-tagged PD-L1 or PD-1 Fc Chimera) or a reference cell. As shown in Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C, compound <bold>2</bold> bound to PD-L1 but not PD-1. The K<sub>D</sub> of <bold>2</bold> binding to PD-L1 was calculated to be 77.60&#8201;&#177;&#8201;4.44&#160;nM by affinity analysis from the curve fitted to the RU values at equilibrium <italic toggle="yes">versus</italic> the concentrations of <bold>2</bold> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>D).</p></sec><sec id="Sec5"><title>T-cell activation recovery assay</title><p id="Par8">To evaluate the capability of <bold>2</bold> to prevent T cell inactivation through PD-L1, we planned to co-culture MDA-MB-231 cells with Jurkat (E6-1) cells pre-activated with anti-CD3 and anti-CD28 antibodies in the presence of <bold>2</bold> or related compounds, namely <bold>5</bold> and <bold>11</bold>, and assessed &#947;-interferon (IFN-&#947;) and interleukin 2 (IL-2) production by ELISA. Prior to conducting tests, we confirmed the expression of PD-L1 on MDA-MB-231 cells and PD-1 on Jurkat (E6-1) cells activated with anti-CD3 and anti-CD28 antibodies, respectively, by Fluorescence Activated Cell Sorting (FACS) (see Sect.&#160;2 in Supplementary Information). In the following tests, we used CA-170, BMS-1, and BMS-1166 as reference compounds. First, we evaluated the cell viability of Jurkat (E6-1) and MDA-MB-231 cells treated with these compounds (1, 10 and 100 &#181; M) by WST-8 assay (Dojindo, Kumamoto, Japan) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). The viability of Jurkat (E6-1) cells treated with <bold>2</bold>, CA-170 and BMS-1166 remained above 85% compared with the control at 1 and 10&#160;&#956;M, while BMS-1, <bold>5</bold> and <bold>11</bold> reduced it to 58.6%, 74.9% and 67.5%, respectively, at 10&#160;&#956;M. The viability of MDA-MB-231 cells treated with 1 and 10 &#181;M of the test compounds remained above 80% except for BMS-1 (78.1% at 10&#160;&#181;M). As shown in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B, CA-170 and <bold>2</bold> significantly increased the IFN-&#947; and IL-2 levels at a non-/low-toxic concentration (10&#160;&#956;M) relative to the control (containing pre-activated Jurkat (E6-1) cells and MDA-MB-231). Compound <bold>2</bold> increased the IFN-&#947; level by 54.9% at 10&#160;&#181;M, and the IL-2 level by 130% at 10&#160;&#181;M. In Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>C, we examined the effect of compound <bold>2</bold> on cytokine secretion in MDA-MB-231 cells or in Jurkat (E6-1), together with BMS-1 as a reference compound. The results showed that <bold>2</bold> had little effect on the cytokine secretion from MDA-MB-231 cells (see blue dotted lines), whereas it somewhat inhibited the cytokine secretion from activated Jurkat (E6-1) cells (black dotted lines). However, the triple combination of compound <bold>2</bold>, MDA-MB-231 and activated Jurkat (E6-1) cells promoted cytokine production (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>B), leading us to conclude that <bold>2</bold> has promising T cell activation recovery activity.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Effect of <bold>2</bold> and related compounds on IFN-&#947; and IL-2 secretion from Jurkat T cells. (<bold>A</bold>) Jurkat (E6-1) and MDA-MB-231 cell viability. *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 <italic toggle="yes">versus</italic> the control (0.1% DMSO/medium). (<bold>B</bold>), (<bold>C</bold>) IFN-&#947; and IL-2 secretion from Jurkat (E6-1) cells. The cytokine secretions in Jurkat (+&#8201;anti-CD3/CD28)&#8201;+&#8201;MDA-MB-231 were used as controls in <bold>B</bold>. The cytokine secretions in MDA-MB-231 only and in Jurkat (+&#8201;anti-CD3/CD28) only were used as controls, respectively, in (<bold>C</bold>). Each value is the mean&#8201;&#177;&#8201;standard error of the mean from triplicate measurements. *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01 <italic toggle="yes">versus</italic> control. All experiments were repeated more than three times and yielded similar results.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e696" position="float" orientation="portrait" xlink:href="41598_2025_17982_Fig3a_HTML.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e697" position="float" orientation="portrait" xlink:href="41598_2025_17982_Fig3b_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title>Docking simulation of BMS-202 and compound 2 into the PD-L1 dimer</title><p id="Par9">As shown in Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A, BMS-1 and BMS-202 have virtually the same pharmacophore. Based on the hypothesis that the hydrophobic part of these compounds and that of compound <bold>2</bold> overlap, we docked <bold>2</bold> with the PD-L1 dimer based on the X-ray data of the PD-L1 tetramer co-crystallized with BMS-202 (<bold>PDB: 5J89</bold>)<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. We conducted the computer simulation using Molecular Operating Environment (MOE) 2028.09. Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref>B displays the area around the docking site of BMS-202 to the PD-L1 dimer. The letters c and d label amino acids belonging to the PD-L1 dimers PD-L1<sub><italic toggle="yes">C</italic></sub> and PD-L1<sub><italic toggle="yes">D</italic></sub><sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. BMS-202 is stabilized by &#960;-alkyl interactions between aromatic ring A and Met<sub><italic toggle="yes">C</italic></sub>115, and aromatic ring B and Ala<sub><italic toggle="yes">C</italic></sub>121. Furthermore, the pyridine ring (C ring) in the linker part of BMS-202 forms a tight hydrophobic interaction with Asp<sub><italic toggle="yes">C</italic></sub>122, whereas the <sup>+</sup>NH<sub>2</sub> and NH of the hydrocarbon chain of BMS-202 form electrostatic interactions with the carbonyl and hydroxyl of the carboxylic acid in Asp<sub><italic toggle="yes">C</italic></sub>122, respectively, enhancing the fit of the linker part of BMS-202 in the cleft at the dimeric interface. Meanwhile, the docking of compound <bold>2</bold> on the PD-L1 dimer (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>C) revealed no interaction between the aromatic ring (A ring) of the benzoylamido group and Met<sub><italic toggle="yes">C</italic></sub>115 or Ala<sub><italic toggle="yes">C</italic></sub>121. Instead, the sulfur atom of the disulfide bond of <bold>2</bold> forms a non-covalent sulfur-disulfide interaction with Met<sub><italic toggle="yes">D</italic></sub>115<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. In addition, the carbonyl group of <bold>2</bold> forms a hydrogen bond with the NH of Tyr<sub><italic toggle="yes">C</italic></sub>123, and the aromatic ring D of <bold>2</bold> binds to the pocket through a &#960;-alkyl interaction with Asn<sub><italic toggle="yes">D</italic></sub> 63. Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref>D shows a simulated docking diagram.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Docking diagram of BMS-202 and compound <bold>2</bold> with the PD-L1 dimer. (<bold>A</bold>) Pharmacophores of BMS-1, BMS-202, and <bold>2</bold>. (<bold>B</bold>) Docking of BMS-202 with the PD-L1 dimer. (<bold>C</bold>) Docking of <bold>2</bold> with the PD-L1 dimer. (<bold>D</bold>) Superimposed models of BMS-202 (magenta) and <bold>2</bold> (cyan) in the PD-L1 dimer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="41598_2025_17982_Fig4_HTML.jpg"/></fig></p><p id="Par10">where BMS-202 (magenta) and <bold>2</bold> (cyan) overlap. The A, B, and C rings of both compounds are well superimposed. However, the disulfide bond linkage in <bold>2</bold> binds to the cleft with a slightly different conformation from the corresponding linker in BMS-202 because Met<sub><italic toggle="yes">D</italic></sub>115 draws the sulfur atom of the disulfide bond in <bold>2</bold> upward. Considering that compound <bold>16</bold>, with &#8211;CH<sub>2</sub>&#8211;O&#8211; instead of the disulfide linkage, did not inhibit PD-1/PD-L1 binding, the non-covalent interaction between the sulfur of <bold>2</bold> and Met<sub><italic toggle="yes">D</italic></sub>115 may play an important role in the inhibition of the PD-1/PD-L1 interaction.</p></sec><sec id="Sec7"><title>Oral administration of compound 2, 7, and oseltamivir to mice with IFV (A/NWS/33, H1N1 subtype)</title><p id="Par11">
We orally administered <bold>2</bold>, its monomeric prodrug <bold>7</bold> (each 1&#160;mg/mouse/day), and oseltamivir (0.2&#160;mg/mouse/day) (suspended in distilled water) to BALB/c mice (n&#8201;=&#8201;10 per group) after intranasal inoculation of IFV (day 0). We evaluated their therapeutic efficacies on IFV-infected mice by monitoring the body weight, survival rate, virus yields in lungs, and neutralizing antibody titers in the bronchoalveolar lavage fluids (BALFs) and serum. Mice infected with IFV did not show symptoms, such as sneezing or nasal discharge. We determined the severity of influenza symptoms based on the weight loss associated with a decrease in appetite due to the onset of pneumonia. The groups treated with <bold>2</bold> and <bold>7</bold> gradually lost body weight until one week after infection, but not as much as the control group. Additionally, <bold>2</bold>- and <bold>7</bold>-treated mice rapidly recovered weight and returned to their original weight two weeks after infection (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A). Therefore, these compounds alleviated the symptoms of viral infection. All mice in all groups survived. On day 3, compounds <bold>2</bold> and <bold>7</bold> had reduced the virus yields in the lungs to 45% (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) and 56% (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) relative to the control, respectively, and oseltamivir had reduced it to 11% (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B). We assessed the effects of the compounds on neutralizing antibody responses to IFV infection in serum and BALF samples on days 3 and 14. On day 3, the antibody titers in the sera of the three administration groups were almost equivalent to that of the control, and there was no significant difference between them (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C). Antibody titers in the lungs could not be measured due to residual virus. On day 14, <bold>2</bold> increased the antibody titers 2.4-fold in BALFs (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>D) and 1.7-fold in sera (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>E) compared with the control group (each <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05). Meanwhile, <bold>7</bold> moderately increased the antibody titers. In contrast, oseltamivir significantly suppressed antibody production compared with the control.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Effects of <bold>2</bold> and <bold>7</bold> on the weight, influenza A virus titers, and neutralizing antibody titers in mice. (<bold>A</bold>) Body weight change for 14&#160;days. (<bold>B</bold>) Virus titers (&#215;&#8201;10<sup>5</sup> plaque-forming units/100&#160;mg) in lung samples of mice on day 3. **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 <italic toggle="yes">versus</italic> control mice (distilled water). (<bold>C</bold>) Neutralizing antibody titers in sera on day 3. (<bold>D</bold>) Neutralizing antibody titers in BALFs on day 14. *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 <italic toggle="yes">versus</italic> control mice. (<bold>E</bold>) Neutralizing antibody titers in sera on day 14. *<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 <italic toggle="yes">versus</italic> control mice.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="41598_2025_17982_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec8"><title><italic toggle="yes">In vitro</italic> anti-influenza virus activity of compound 2</title><p id="Par12">In order to investigate the possibility that the influenza therapeutic effect of compound <bold>2</bold> is due to its direct antiviral activity, we evaluated the <italic toggle="yes">in vitro</italic> antiviral activity of <bold>2</bold> against IFV. The CC<sub>50</sub> of <bold>2</bold> was 20&#8201;&#177;&#8201;2.1 &#181;g/mL against Madin&#8211;Darby canine kidney epithelial (MDCK) cells. The EC<sub>50</sub> of <bold>2</bold> was 110&#8201;&#177;&#8201;9.2&#160;&#181;g/mL. The resulting selectivity index (CC<sub>50</sub>/EC<sub>50</sub>) was 0.18&#8201;&#177;&#8201;0.035.</p></sec></sec><sec id="Sec9"><title>Discussion</title><p id="Par13">
The ELISA and SPR assays demonstrated that <bold>2</bold> inhibited the PD-1/PD-L1 binding and selectively bound to PD-L1 over PD-1. Furthermore, the T-cell activation recovery results suggested that <bold>2</bold> activated T cell function by inhibiting the PD-1/PD-L1 interaction. We initially inferred that the disulfide group of <bold>2</bold> bounded with a thiol of cysteine in the PD-L1 binding pocket through a thiol-disulfide exchange reaction. However, the docking simulation suggested that one sulfur atom of the disulfide group of <bold>2</bold> interacted non-covalently with the sulfur atom of Met<italic toggle="yes">D</italic>115, assisting the binding between <bold>2</bold> and the PD-L1 dimer. We speculate that this interaction, as well as the electrostatic and hydrophobic interactions by the carbonyl and aromatic D ring of <bold>2</bold>, respectively, could compensate for the lack of electrostatic binding sites, which are present in BMS-1 and BMS-202. This binding mode involving a disulfide group has not been found in previous small-molecule PD-1/PD-L1 inhibitors.</p><p id="Par14">The oral administration of <bold>2</bold> to mice after the intranasal infection of IFV (A/NWS/33, H1N1 subtype) not only alleviated symptoms and reduced viral production in the lung, but also increased neutralizing antibody titers. It is well known that there are concerns in the development of vaccines against viral diseases, such as COVID-19 and influenza, and that antibody levels are not maintained over the long term<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. There are several reports regarding the application of immune checkpoint inhibitors to treat viral diseases<sup><xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref></sup>. However, they have not been used in practice due to the risk of side effects such as an excessive immune activation (immune-related pneumonia)<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Compound <bold>2</bold> rescued mice from influenza-induced pneumonia and induced a high increase in neutralizing antibody titers. In general, when a compound has a selectivity index greater than 10, it can be regarded as possessing <italic toggle="yes">in vitro</italic> antiviral activity. Compound <bold>2</bold> showed the selectivity index of 0.18&#8201;&#177;&#8201;0.035, strongly suggesting that its antiviral effect is not due to a direct inhibition of viral replication in the influenza virus-infected mice. Furthermore, since compound <bold>2</bold> blocked not only human PD-1/PD-L1 interaction, but also mouse PD-1/PD-L1 interaction in ELISA (see Sect.&#160;3 in Supplementary Information), it is most likely that <bold>2</bold> rescued mice from influenza-induced pneumonia through a mechanism involving inhibition of PD-1/PD-L1 interaction. We anticipate that <bold>2</bold> or a similar compound may be used as a new type of therapeutic drug for virus-infected patients that can extend the vaccine effectiveness. Notably, <bold>2</bold> also selectively inhibited HDAC6 (see Sect.&#160;4 in Supplementary Information). Since inhibiting HDAC6 downregulates PD-L1 expression<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>, <bold>2</bold> may act as a dual targeting inhibitor. These findings strongly support the application of <bold>2</bold> or related compounds in therapeutics for viral diseases, including early stage infectious diseases<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR48">48</xref></sup>.</p><p id="Par15">Small molecule immune checkpoint inhibitors are generally less effective than antibody drugs, and there are concerns about side effects due to off-target effects, making their development difficult. However, some small molecule drugs having multiple mechanisms of action on the market are referred to as &#8220;dirty drugs,&#8221; and are actually more effective than drugs with a single mechanism. Since small molecule immune checkpoint inhibitors are expected to possess many advantages compared to the antibody drugs as described at the beginning, they might have a potential to be used as medicines particularly for early symptoms of diseases. For example, they might be developed as medicines for early symptoms of coronavirus infection and influenza virus infection as described above, because their efficacies are somewhat milder than those of the antibody drugs.</p><p id="Par16">Compound <bold>2</bold> is commercially available as 2&#8217;,2&#8217;&#8217;&#8217;-dithiobisbenzanilide (DTBBA) and is used as a rubber peptizing agent in the manufacturing process of tires and other rubber products. Additionally, the tire and rubber wear particles are distributed in the environment<sup><xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR53">53</xref></sup>. However, only a few studies have considered the effect of DTBBA on living organisms<sup><xref ref-type="bibr" rid="CR49">49</xref>&#8211;<xref ref-type="bibr" rid="CR51">51</xref></sup>. We believe that our paper will provide valuable information for investigating the effects on organisms.</p></sec><sec id="Sec10"><title>Methods</title><sec id="Sec11"><title>Ethics statement</title><p id="Par17">Committees from the Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, and Faculty of Chemistry, Materials and Bioengineering, Kansai University approved the experimental protocols. All animal experiments were performed in accordance with the animal experimentation guidelines of Chubu University and were approved by the Animal Care Committee of Chubu University (permission number: 3010057). All infections and sample collections were conducted under anesthesia with sodium pentobarbital (50&#160;mg/kg), and human endpoints were used during the study, that is, animals with&#8201;&gt;&#8201;20% weight loss within 2&#160;days were sacrificed using sodium pentobarbital treatment (150&#160;mg/kg). The results were reported in accordance with ARRIVE guidelines. No side effects such as diarrhea were observed due to drug administration throughout the experiments.</p></sec><sec id="Sec12"><title>General procedures</title><p id="Par18">BMS-1 and BMS-1166 were purchased from Cayman Chemical (MI, USA), and CA-170 was purchased from MedChem Express (NJ, USA). We described the synthetic methods of compounds <bold>1</bold>&#8211;<bold>3</bold>, <bold>6</bold>&#8211;<bold>8</bold>, and <bold>17</bold> in our previous paper<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. The synthesis of all other compounds and purity of test compounds are provided as Sects.&#160;5 and 6 in Supplementary Information, respectively. The PD-1/PD-L1 inhibition assay and SPR analysis were performed using PD-1 Fc Chimera and His-tagged PD-L1, which we purchased from Genscript (NJ, USA) and Sino Biological (Beijing, China), respectively. We purchased Biacore T200 from Cytiva (MA, USA).</p></sec><sec id="Sec13"><title>Cells and virus</title><p id="Par19">MDCK cells and IFV (A/NWS/33, H1N1 subtype) were obtained from Denka Seiken Co., Ltd. (Tokyo, Japan). The cells were grown in minimum essential medium (MEM) supplemented with 5% fetal bovine serum, 100&#160;units/mL penicillin G and 100&#160;mg/mL streptomycin. Jurkat cells (E6-1) and MDA-MB-231cells were purchased from American Type Culture Collection (ATCC).</p></sec><sec id="Sec14"><title>Biotinylation of PD-1</title><p id="Par20">We biotinylated the PD-1 Fc Chimera using a CromaLink<sup>&#174;</sup> Biotin labeling kit (TriLink, CA, USA) and desalted it by ultrafiltration using a 10&#160;kDa-cutoff Vivaspin column (Cytiva, MA, USA). We determined the degree of biotinylation by employing a 4&#8217;-hydroxyazobenzene-2-carboxylic acid (HABA) assay<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Briefly, we added a solution of biotinylated PD-1 in deionized water (20&#160;&#956;L) to an aliquot (180&#160;&#956;L) of a mixture of avidin (5&#160;mg) and HABA (726&#160;&#956;g) in PBS (9.7&#160;mL) and deionized water (300&#160;&#956;L, containing 1N NaOH (3&#160;&#956;L)) (Pierce Chemical Co., Rockford, IL, USA). We then measured the absorbance at 500&#160;nm using a microplate reader. The biotinylation percentage, calculated by dividing the biotynilated protein concentration by the total protein concentration, was approximately 0.27/protein.</p></sec><sec id="Sec15"><title>PD-1/PD-L1 inhibition assay with ELISA</title><p id="Par21">We treated Ni-coated 96-well plates (Thermo Scientific Pierce, MA, USA) with 0.25&#160;&#956;M/100&#160;&#956;L/well of His-tagged PD-L1 and washed them using Tris-buffered saline with Tween 20 (TBS-T) (pH 7.2). We plotted standard curves using the wells with 0&#8211;1.0&#160;&#956;M/mL biotinylated PD-1 Fc Chimera in each plate. We diluted the test compounds or BMS-1 (all at 10&#160;mM in DMSO) in 20% Blocking One (Nacalai Tesque, Kyoto, Japan) to reach 100&#160;&#956;M. Next, we placed the mixture (100&#160;&#956;L) of the compound (10&#160;&#956;L, final concentration: 10&#160;&#956;M) and PD-1 (90&#160;&#956;L, final concentration: 0.25&#160;&#956;M) into the 96-well plate with His-tagged PD-L1. After incubation for 1&#160;h, we washed the plate with TBST (pH 7.2) and detected bound PD-1 by adding streptavidin-HRP (R&amp;D Systems, MN, USA) and then colorizing with a TMB solution (Nacalai Tesque, Kyoto, Japan) in a conventional manner. We calculated percentage binding ratios by diving the absorbance at 450&#160;nm obtained from the co-incubation of PD-1/PD-L1 and test compound by the absorbance obtained from the incubation of these proteins alone.</p></sec><sec id="Sec16"><title>SPR analysis</title><p id="Par22">We performed the binding assay of PD-L1 and PD-1 and evaluated the inhibition of the PD-L1 and PD-1 interaction using a Biacore T200 system with a Sensor Chip CM5 (Cytiva, MA, USA). We injected His-tagged PD-L1 (final concentration: 1.0&#160;&#956;M) in sodium acetate buffer (pH 4.0) through a ligand cell to allow immobilization on the Sensor Chip CM5 by condensation between -COOH and NH<sub>2</sub>- using <italic toggle="yes">N-</italic>hydroxysuccinimide and water-soluble carbodiimide hydrochloride (WSCI HCl). We then blocked the residual -COOH groups on the Sensor Chip CM5 using ethanolamine. The immobilization response of His-tagged PD-L1 was 2793&#160;RU. In the reference cell, we blocked all the -COOH groups of CM5 with ethanolamine. Then, we diluted the PD-1 Fc Chimera with the running buffer (1&#8201;&#215;&#8201;HBS-EP buffer) (Cytiva, MA, USA) to reach final concentrations of 0.001, 0.125, 0.25, 0.5, and 1.0&#160;&#956;M (100&#160;&#956;L of each). We then injected these solutions through a ligand or reference cell. We set the contact time at 60&#160;s and the flow rate at 10&#160;&#956;L/min for PD-L1 capture. We regenerated the surface after each cycle using 10&#160;mM glycine (pH 1.5) (Cytiva, MA, USA) at a flow rate of 30&#160;&#956;L/min for 30&#160;s. We calculated the experimental Rmax using the Biacore T200 Evaluation Software version 1.0 and the Biacore 1&#160;K<sup>+</sup> Evaluation Software version 6.0 (Cytiva, MA, USA). Next, we diluted <bold>2</bold> or BMS-1 with the running buffer to reach final concentrations of 0.1 and 0.01&#160;&#956;M (containing 1% DMSO); we diluted the PD-1 Fc Chimera to 0.1&#160;&#956;M using the same buffer (containing 1% DMSO). Then, we pre-mixed the test compounds (10&#160;&#956;L; final concentrations: 0.1 or 0.01&#160;&#956;M) and PD-1 Fc Chimera (90&#160;&#956;L; final concentration: 0.1&#160;&#956;M) for 60&#160;min at room temperature (r.t.) and injected these solutions (100&#160;&#956;L) through a ligand or reference cell. We calculated the experimental Rmax using the Biacore Evaluation software. For the binding assays of <bold>2</bold> to PD-L1 or PD-1, we injected His-tagged PD-L1 (final concentration, 1.0&#160;&#956;M, pH 6.0) or PD-1 Fc Chimera (final concentration, 1.0&#160;&#956;M, pH 4.0) on a Biacore Sensor Chip CM5 to immobilize them. The immobilization responses of His-tagged PD-L1 and PD-1 Fc Chimera were 138.4 and 155.5 RU, respectively. Then, we diluted <bold>2</bold> with the running buffer to reach final concentrations of 0.01, 0.1, 0.5, and 1.0&#160;&#956;M (100&#160;&#956;L of each, containing 5% DMSO) and injected them through a ligand or reference cell. We performed the affinity analysis at r.t. We calculated the Rmax and K<sub>D</sub> values using the Biacore T200 Evaluation software and Excel.</p></sec><sec id="Sec17"><title>Effects of BMS-1, CA-170, BMS-1166, 2, 5, and 11 on the viability of Jurkat (E6-1) and MDA-MB-231 cells</title><p id="Par23">We seeded Jurkat (E6-1) (4&#8201;&#215;&#8201;10<sup>4</sup>&#160;cells/well) and MDA-MB-231 (2&#8201;&#215;&#8201;10<sup>4</sup>&#160;cells/well) cells onto standard 96-well microtiter plates. Following 24&#160;h of culture, we added the test compounds (1, 10, or 100&#160;&#956;M) to the wells. After 24&#160;h of incubation, we evaluated cell growth using a WST-8 assay kit (Dojindo, Kumamoto, Japan).</p></sec><sec id="Sec18"><title>T cell activation recovery assay</title><p id="Par24">We cultured Jurkat (E6-1) cells in RPMI 1640 Medium (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, MO, USA) and 0.5% penicillin/streptomycin at 37&#160;&#176;C in a 95% air and 5% CO<sub>2</sub> humidified incubator. To an aliquot (10&#160;mL (1&#8201;&#215;&#8201;10<sup>6</sup>&#8211;1&#8201;&#215;&#8201;10<sup>7</sup>&#160;cells/mL)) of this culture medium, we added ImmunoCult&#8482; Human CD3/CD28 T cell activator (250&#160;&#956;L) (Stem Cell Technologies, Vancouver, BC, Canada). After incubating for 72&#160;h, we monitored T cell activation by measuring IL-2 and IFN-&#947; production using a strips-type ELISA plate (Sepaplate-8F, Sumitomo Bakelite Co., Ltd., Tokyo, Japan). Meanwhile, we cultured the MDA-MB-231 cells in DMEM containing 10% FBS and 0.5% penicillin/streptomycin, seeded them in 96-well plates at 1&#8201;&#215;&#8201;10<sup>4</sup> cells/well, and incubated them for 24&#160;h. Then, we added the T cell-activated Jurkat cell culture solution (100&#160;&#956;L) containing 4&#8201;&#215;&#8201;10<sup>4</sup> cells and the test compound (1, 10, or 100&#160;&#956;M) to the 96-well plate with the MDA-MB-231 cell culture solution, and incubated for 24&#160;h. We then collected the supernatants and evaluated the production of IL-2 and IFN-&#947; using the ELISA MAX Deluxe Set Human IL-2 (Biolegend, CA, USA) and ELISA MAX&#8482; Deluxe Set Human IFN-&#947; (Biolegend, CA, USA).</p><p id="Par25">In the same way, we tested the cytokine levels in MDA-MB-231 and anti-CD3/CD28-activated Jurkat (E6-1) cell culture solutions, respectively, without or with a test compound.</p></sec><sec id="Sec19"><title>Molecular docking</title><p id="Par26">As a PD-L1 structure reference, we used the X-ray data of BMS-202 co-crystallized with PD-L1 (<bold>PDB: 5J89</bold>). We docked <bold>2</bold> with PD-L1 using MOE 2022.09, with Amber10: EHT as the force field. We used standard protocols for general docking. We ranked the obtained docked poses using the London dG score, then performed force field refinement for the top 30 poses, and rescored them using GBVI/WSA dG (Induced Fit).</p></sec><sec id="Sec20"><title>Mouse experiments</title><p id="Par27">Female BALB/c mice (5&#8211;6&#160;weeks old) were purchased from Japan SLC (Shizuoka, Japan). On day 0, mice (n&#8201;=&#8201;10 per group) were intranasally infected with 2&#8201;&#215;&#8201;10<sup>4</sup> PFU of IFV in 50&#160;&#956;L of PBS. They then received orally <bold>2</bold>, <bold>7</bold> (each 1&#160;mg/0.4&#160;mL distilled water), or oseltamivir phosphate (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) (0.2&#160;mg/0.4&#160;mL distilled water) once a day (at 9:00 am) from day 0 to day 14, beginning 5&#160;min after virus infection. Control mice received 0.4&#160;mL of vehicle (distilled water). Body weight and mortality were monitored for 14&#160;days after virus inoculation. On day 3, lung samples were collected from each group (n&#8201;=&#8201;5 per group), treated with 1&#160;&#956;L of PBS per mg of lung tissue, sonicated for 10&#160;s, and centrifuged at 10,000&#160;rpm for 30&#160;min. The supernatants were stored at&#8201;&#8722;&#8201;80&#160;&#176;C. Virus titers of these samples were determined by plaque assay on MDCK cell monolayers. Blood samples and BALFs were collected from each group on days 3 and 14. The blood samples were centrifuged them at 3000&#160;rpm for 10&#160;min, and the sera were stored at&#8201;&#8722;&#8201;20&#160;&#176;C. BALF samples were prepared by performing four washes with 0.8&#160;mL of ice-cold PBS using a tracheal cannula, centrifuged them at 1500&#160;rpm for 10&#160;min, and the supernatants were stored at&#8201;&#8722;&#8201;80&#160;&#176;C. Neutralizing antibody titers on days 3 and 14 were determined by performing a 50% plaque reduction assay as previously described<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>.</p></sec><sec id="Sec21"><title>In vitro anti-IFV assays</title><p id="Par28">Compound <bold>2</bold> was dissolved in DMSO. The working solutions of <bold>2</bold> and control without <bold>2</bold> contained&#8201;&lt;&#8201;0.2% DMSO, which did not interfere with the growth of both MDCK cells and IFV (see Sect.&#160;7 in Supplementary Information). For cytotoxicity assay, MDCK cells were seeded at a density of 1&#8201;&#215;&#8201;10<sup>4</sup> cells/well in 96-well plates. After 24&#160;h incubation at 37&#160;&#176;C, the cells were cultured for 72&#160;h in the presence of <bold>2</bold> (0&#8211;1000&#160;&#181;g/mL). Viable cell yields were determined by the trypan blue exclusion test. The inhibition data were plotted as dose&#8211;response curves, from which the 50% cell growth inhibitory concentration (CC<sub>50</sub>) was obtained. In anti-IFV assays, the plaque yield reduction assay was employed. MDCK cell monolayers in 48-well plates were infected with IFV at 0.1 plaque-forming unit (PFU)/cell for 1&#160;h at r.t. (26&#160;&#176;C). After washing the cell monolayers with phosphate-buffered saline the cells were further incubated at 37&#160;&#176;C for 24&#160;h in the presence of <bold>2</bold>. Virus yields in each well were determined using plaque assays, and the 50% effective concentration (EC<sub>50</sub>) was obtained from the concentration&#8211;response curves. The antiviral activity of <bold>2</bold> against IFV was estimated using the selectivity index calculated from the CC<sub>50</sub> and EC<sub>50</sub>. Data are shown as the mean&#8201;&#177;&#8201;SD from independent triplicate assays.</p></sec><sec id="Sec22"><title>Statistical analysis</title><p id="Par29">Data are expressed as the mean&#8201;&#177;&#8201;standard deviation. We compared the samples with the control using student&#8217;s <italic toggle="yes">t</italic>-tests.</p></sec><sec id="Sec23"><title>Reporting summary</title><p id="Par30">Further information on the research design is available in the Nature Reporting Summary linked to this article.</p></sec></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_17982_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Information.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank MS Hinata Nishino and BS He Zhaoyang at Kansai University for their assistance with the ELISA measurements, synthesis of some inhibitors, and measurement of NMR and MS spectra. We also thank Dr. Yasuyuki Kawaratani and MS Akinori Kozatani at Kansai University for their support in constructing the sulfur-containing compound library.</p></ack><notes notes-type="author-contribution"><title><bold>Author contributions</bold></title><p>S.U. and Y.H. contributed equally to this work. S.U. supervised the entire study and drafted the manuscript. S.U., Y.H., Y.N., K.H., T.K., and M.D. interpreted data and approved the final manuscript. S.U. designed and supervised the synthesis of the evaluated compounds. Y.H. performed all in vitro assays. K.H. performed the in vivo virus infection experiments. T.K. and M.D. conducted the molecular docking simulations.</p></notes><notes notes-type="data-availability"><title><bold>Data availability</bold></title><p>The data generated or analyzed during this study are included in this published article and its supplementary information files. The data are available upon request from the corresponding author.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par31">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>X</given-names></name><etal/></person-group><article-title>The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>19393</fpage><lpage>19404</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5107</pub-id><pub-id pub-id-type="pmid">26305724</pub-id><pub-id pub-id-type="pmcid">PMC4637293</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sui, X. et al. The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <italic toggle="yes">Oncotarget</italic><bold>6</bold>, 19393&#8211;19404 (2015).<pub-id pub-id-type="pmid">26305724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.5107</pub-id><pub-id pub-id-type="pmcid">PMC4637293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmer</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Safety and activity of anti&#8211;PD-L1 antibody in patients with advanced cancer</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>366</volume><fpage>2455</fpage><lpage>2465</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200694</pub-id><pub-id pub-id-type="pmid">22658128</pub-id><pub-id pub-id-type="pmcid">PMC3563263</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Brahmer, J. R. et al. Safety and activity of anti&#8211;PD-L1 antibody in patients with advanced cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>366</bold>, 2455&#8211;2465 (2012).<pub-id pub-id-type="pmid">22658128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1200694</pub-id><pub-id pub-id-type="pmcid">PMC3563263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topalian</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Safety, activity, and immune correlates of anti&#8211;PD-1 antibody in cancer</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>366</volume><fpage>2443</fpage><lpage>2454</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1200690</pub-id><pub-id pub-id-type="pmid">22658127</pub-id><pub-id pub-id-type="pmcid">PMC3544539</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Topalian, S. L. et al. Safety, activity, and immune correlates of anti&#8211;PD-1 antibody in cancer. <italic toggle="yes">N. Engl. J. Med.</italic><bold>366</bold>, 2443&#8211;2454 (2012).<pub-id pub-id-type="pmid">22658127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1200690</pub-id><pub-id pub-id-type="pmcid">PMC3544539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.03.030</pub-id><pub-id pub-id-type="pmid">25860605</pub-id><pub-id pub-id-type="pmcid">PMC5905674</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sharma, P. &amp; Allison, J. P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. <italic toggle="yes">Cell</italic><bold>161</bold>, 205&#8211;214 (2015).<pub-id pub-id-type="pmid">25860605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.03.030</pub-id><pub-id pub-id-type="pmcid">PMC5905674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topalian</surname><given-names>SL</given-names></name><name name-style="western"><surname>Drake</surname><given-names>CG</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>Immune checkpoint blockade: A common denominator approach to cancer therapy</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><fpage>450</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.03.001</pub-id><pub-id pub-id-type="pmid">25858804</pub-id><pub-id pub-id-type="pmcid">PMC4400238</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Topalian, S. L., Drake, C. G. &amp; Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. <italic toggle="yes">Cancer Cell</italic><bold>27</bold>, 450&#8211;461 (2015).<pub-id pub-id-type="pmid">25858804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2015.03.001</pub-id><pub-id pub-id-type="pmcid">PMC4400238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahoney</surname><given-names>KM</given-names></name><name name-style="western"><surname>Rennert</surname><given-names>PD</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>GJ</given-names></name></person-group><article-title>Combination cancer immunotherapy and new immunomodulatory targets</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>561</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1038/nrd4591</pub-id><pub-id pub-id-type="pmid">26228759</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Mahoney, K. M., Rennert, P. D. &amp; Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>14</bold>, 561&#8211;584 (2015).<pub-id pub-id-type="pmid">26228759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd4591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patnaik</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase I study of pembrolizumab (MK-3475; anti&#8211;PD-1 monoclonal antibody) in patients with advanced solid tumors</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>4286</fpage><lpage>4293</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2607</pub-id><pub-id pub-id-type="pmid">25977344</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Patnaik, A. et al. Phase I study of pembrolizumab (MK-3475; anti&#8211;PD-1 monoclonal antibody) in patients with advanced solid tumors. <italic toggle="yes">Clin. Cancer Res.</italic><bold>21</bold>, 4286&#8211;4293 (2015).<pub-id pub-id-type="pmid">25977344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-14-2607</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>DN</given-names></name><etal/></person-group><article-title>The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2016</year><volume>13</volume><fpage>273</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.25</pub-id><pub-id pub-id-type="pmid">26977780</pub-id><pub-id pub-id-type="pmcid">PMC5551685</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Khalil, D. N. et al. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. <italic toggle="yes">Nat. Rev. Clin. Oncol.</italic><bold>13</bold>, 273&#8211;290 (2016).<pub-id pub-id-type="pmid">26977780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2016.25</pub-id><pub-id pub-id-type="pmcid">PMC5551685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoos</surname><given-names>A</given-names></name></person-group><article-title>Development of immuno-oncology drugs&#8212;From CTLA4 to PD1 to the next generations</article-title><source>Nat. Rev. Drug Discov.</source><year>2016</year><volume>15</volume><fpage>235</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/nrd.2015.35</pub-id><pub-id pub-id-type="pmid">26965203</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Hoos, A. Development of immuno-oncology drugs&#8212;From CTLA4 to PD1 to the next generations. <italic toggle="yes">Nat. Rev. Drug Discov.</italic><bold>15</bold>, 235&#8211;247 (2016).<pub-id pub-id-type="pmid">26965203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2015.35</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanella</surname><given-names>V</given-names></name><etal/></person-group><article-title>PD-L1 Inhibitors in the pipeline: Promise and progress</article-title><source>Oncoimmunology</source><year>2017</year><volume>7</volume><fpage>e1365209</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2017.1365209</pub-id><pub-id pub-id-type="pmid">29296516</pub-id><pub-id pub-id-type="pmcid">PMC5739559</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Vanella, V. et al. PD-L1 Inhibitors in the pipeline: Promise and progress. <italic toggle="yes">Oncoimmunology</italic><bold>7</bold>, e1365209 (2017).<pub-id pub-id-type="pmid">29296516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2017.1365209</pub-id><pub-id pub-id-type="pmcid">PMC5739559</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name></person-group><article-title>Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules</article-title><source>Med. Res. Rev.</source><year>2019</year><volume>39</volume><fpage>265</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1002/med.21530</pub-id><pub-id pub-id-type="pmid">30215856</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Yang, J. &amp; Hu, L. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. <italic toggle="yes">Med. Res. Rev.</italic><bold>39</bold>, 265&#8211;301 (2019).<pub-id pub-id-type="pmid">30215856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>TH</given-names></name><etal/></person-group><article-title>FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma</article-title><source>Clin. Cancer Res.</source><year>2024</year><volume>30</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-2124</pub-id><pub-id pub-id-type="pmid">37676259</pub-id><pub-id pub-id-type="pmcid">PMC10841291</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Patel, T. H. et al. FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. <italic toggle="yes">Clin. Cancer Res.</italic><bold>30</bold>, 269&#8211;273 (2024).<pub-id pub-id-type="pmid">37676259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-23-2124</pub-id><pub-id pub-id-type="pmcid">PMC10841291</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joller</surname><given-names>N</given-names></name><etal/></person-group><article-title>LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation</article-title><source>Immunity</source><year>2024</year><volume>57</volume><fpage>206</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.01.010</pub-id><pub-id pub-id-type="pmid">38354701</pub-id><pub-id pub-id-type="pmcid">PMC10919259</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Joller, N. et al. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. <italic toggle="yes">Immunity</italic><bold>57</bold>, 206&#8211;222 (2024).<pub-id pub-id-type="pmid">38354701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2024.01.010</pub-id><pub-id pub-id-type="pmcid">PMC10919259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy</article-title><source>J Hematol. Oncol.</source><year>2023</year><volume>16</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s13045-023-01499-1</pub-id><pub-id pub-id-type="pmid">37670328</pub-id><pub-id pub-id-type="pmcid">PMC10478462</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Cai, L. et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. <italic toggle="yes">J Hematol. Oncol.</italic><bold>16</bold>, 101 (2023).<pub-id pub-id-type="pmid">37670328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-023-01499-1</pub-id><pub-id pub-id-type="pmcid">PMC10478462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McNally</surname><given-names>B</given-names></name><etal/></person-group><article-title>Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>12916</fpage><lpage>12924</lpage><pub-id pub-id-type="doi">10.1128/JVI.02423-13</pub-id><pub-id pub-id-type="pmid">24067957</pub-id><pub-id pub-id-type="pmcid">PMC3838157</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">McNally, B. et al. Local blockade of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influenza virus infection. <italic toggle="yes">J. Virol.</italic><bold>87</bold>, 12916&#8211;12924 (2013).<pub-id pub-id-type="pmid">24067957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02423-13</pub-id><pub-id pub-id-type="pmcid">PMC3838157</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boumaza</surname><given-names>X</given-names></name><etal/></person-group><article-title>Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors</article-title><source>Ann. Neurol.</source><year>2023</year><volume>93</volume><fpage>257</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/ana.26512</pub-id><pub-id pub-id-type="pmid">36151879</pub-id><pub-id pub-id-type="pmcid">PMC10092874</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Boumaza, X. et al. Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors. <italic toggle="yes">Ann. Neurol.</italic><bold>93</bold>, 257&#8211;270 (2023).<pub-id pub-id-type="pmid">36151879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.26512</pub-id><pub-id pub-id-type="pmcid">PMC10092874</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wykes</surname><given-names>MN</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>SR</given-names></name></person-group><article-title>Immune checkpoint blockade in infectious diseases</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.112</pub-id><pub-id pub-id-type="pmid">28990586</pub-id><pub-id pub-id-type="pmcid">PMC5991909</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wykes, M. N. &amp; Lewin, S. R. Immune checkpoint blockade in infectious diseases. <italic toggle="yes">Nat. Rev. Immunol.</italic><bold>18</bold>, 91&#8211;104 (2018).<pub-id pub-id-type="pmid">28990586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2017.112</pub-id><pub-id pub-id-type="pmcid">PMC5991909</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>W</given-names></name><etal/></person-group><article-title>PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection</article-title><source>Immunol. Res.</source><year>2016</year><volume>64</volume><fpage>412</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1007/s12026-015-8680-y</pub-id><pub-id pub-id-type="pmid">26286967</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Xiao, W. et al. PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection. <italic toggle="yes">Immunol. Res.</italic><bold>64</bold>, 412&#8211;423 (2016).<pub-id pub-id-type="pmid">26286967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-015-8680-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarczak</surname><given-names>D</given-names></name><name name-style="western"><surname>Nierhaus</surname><given-names>A</given-names></name></person-group><article-title>Cytokine storm&#8212;Definition, causes, and implications</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><fpage>11740</fpage><pub-id pub-id-type="doi">10.3390/ijms231911740</pub-id><pub-id pub-id-type="pmid">36233040</pub-id><pub-id pub-id-type="pmcid">PMC9570384</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Jarczak, D. &amp; Nierhaus, A. Cytokine storm&#8212;Definition, causes, and implications. <italic toggle="yes">Int. J. Mol. Sci.</italic><bold>23</bold>, 11740 (2022).<pub-id pub-id-type="pmid">36233040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms231911740</pub-id><pub-id pub-id-type="pmcid">PMC9570384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name></person-group><article-title>Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors</article-title><source>Immune. Netw.</source><year>2020</year><volume>20</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.4110/in.2020.20.e9</pub-id><pub-id pub-id-type="pmcid">PMC7049586</pub-id><pub-id pub-id-type="pmid">32158597</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Choi, J. &amp; Lee, S. Y. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. <italic toggle="yes">Immune. Netw.</italic><bold>20</bold>, 1&#8211;21 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4110/in.2020.20.e9</pub-id><pub-id pub-id-type="pmcid">PMC7049586</pub-id><pub-id pub-id-type="pmid">32158597</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zak</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>30323</fpage><lpage>30335</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8730</pub-id><pub-id pub-id-type="pmid">27083005</pub-id><pub-id pub-id-type="pmcid">PMC5058683</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zak, K. M. et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). <italic toggle="yes">Oncotarget</italic><bold>7</bold>, 30323&#8211;30335 (2016).<pub-id pub-id-type="pmid">27083005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.8730</pub-id><pub-id pub-id-type="pmcid">PMC5058683</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzik</surname><given-names>K</given-names></name><etal/></person-group><article-title>Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>5857</fpage><lpage>5867</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00293</pub-id><pub-id pub-id-type="pmid">28613862</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Guzik, K. et al. Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. <italic toggle="yes">J. Med. Chem.</italic><bold>60</bold>, 5857&#8211;5867 (2017).<pub-id pub-id-type="pmid">28613862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.7b00293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skalniak</surname><given-names>L</given-names></name><etal/></person-group><article-title>Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>72167</fpage><lpage>72181</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20050</pub-id><pub-id pub-id-type="pmid">29069777</pub-id><pub-id pub-id-type="pmcid">PMC5641120</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Skalniak, L. et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <italic toggle="yes">Oncotarget</italic><bold>8</bold>, 72167&#8211;72181 (2017).<pub-id pub-id-type="pmid">29069777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.20050</pub-id><pub-id pub-id-type="pmcid">PMC5641120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name></person-group><article-title>Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy</article-title><source>J. Drug Target.</source><year>2019</year><volume>27</volume><fpage>244</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2018.1440400</pub-id><pub-id pub-id-type="pmid">29448849</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Li, K. &amp; Tian, H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. <italic toggle="yes">J. Drug Target.</italic><bold>27</bold>, 244&#8211;256 (2019).<pub-id pub-id-type="pmid">29448849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/1061186X.2018.1440400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzik</surname><given-names>K</given-names></name><etal/></person-group><article-title>Development of the inhibitors that target the PD-1/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles</article-title><source>Molecules</source><year>2019</year><volume>24</volume><fpage>2071</fpage><pub-id pub-id-type="doi">10.3390/molecules24112071</pub-id><pub-id pub-id-type="pmid">31151293</pub-id><pub-id pub-id-type="pmcid">PMC6600339</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Guzik, K. et al. Development of the inhibitors that target the PD-1/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles. <italic toggle="yes">Molecules</italic><bold>24</bold>, 2071 (2019).<pub-id pub-id-type="pmid">31151293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules24112071</pub-id><pub-id pub-id-type="pmcid">PMC6600339</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy</article-title><source>Anal. Biochem.</source><year>2018</year><volume>547</volume><fpage>52</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2018.02.003</pub-id><pub-id pub-id-type="pmid">29428377</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Han, Y. et al. PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy. <italic toggle="yes">Anal. Biochem.</italic><bold>547</bold>, 52&#8211;56 (2018).<pub-id pub-id-type="pmid">29428377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ab.2018.02.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basu</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein&#8211;protein interaction</article-title><source>J. Med. Chem.</source><year>2019</year><volume>62</volume><fpage>7250</fpage><lpage>7263</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b00795</pub-id><pub-id pub-id-type="pmid">31298541</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Basu, S. et al. Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein&#8211;protein interaction. <italic toggle="yes">J. Med. Chem.</italic><bold>62</bold>, 7250&#8211;7263 (2019).<pub-id pub-id-type="pmid">31298541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.9b00795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Syntheses, biological evaluations, and mechanistic studies of benzo[c][1,2,5]oxadiazole derivatives as potent PD-L1 inhibitors with in vivo antitumor activity</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>8391</fpage><lpage>8409</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00392</pub-id><pub-id pub-id-type="pmid">34115499</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Liu, L. et al. Syntheses, biological evaluations, and mechanistic studies of benzo[c][1,2,5]oxadiazole derivatives as potent PD-L1 inhibitors with in vivo antitumor activity. <italic toggle="yes">J. Med. Chem.</italic><bold>64</bold>, 8391&#8211;8409 (2021).<pub-id pub-id-type="pmid">34115499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.1c00392</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musielak</surname><given-names>B</given-names></name><etal/></person-group><article-title>CA-170-A potent small-molecule PD-L1 inhibitor or not?</article-title><source>Molecules</source><year>2019</year><volume>24</volume><fpage>2804</fpage><pub-id pub-id-type="doi">10.3390/molecules24152804</pub-id><pub-id pub-id-type="pmid">31374878</pub-id><pub-id pub-id-type="pmcid">PMC6695792</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Musielak, B. et al. CA-170-A potent small-molecule PD-L1 inhibitor or not?. <italic toggle="yes">Molecules</italic><bold>24</bold>, 2804 (2019).<pub-id pub-id-type="pmid">31374878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules24152804</pub-id><pub-id pub-id-type="pmcid">PMC6695792</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasikumar</surname><given-names>PG</given-names></name><etal/></person-group><article-title>PD-1 Derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy</article-title><source>Commun. Biol.</source><year>2021</year><volume>4</volume><fpage>699</fpage><pub-id pub-id-type="doi">10.1038/s42003-021-02191-1</pub-id><pub-id pub-id-type="pmid">34103659</pub-id><pub-id pub-id-type="pmcid">PMC8187357</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sasikumar, P. G. et al. PD-1 Derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. <italic toggle="yes">Commun. Biol.</italic><bold>4</bold>, 699 (2021).<pub-id pub-id-type="pmid">34103659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-021-02191-1</pub-id><pub-id pub-id-type="pmcid">PMC8187357</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Synthesis and peliminary ealuation of ainophenol drivatives as mlecular glues bocking PD-1/PD-L1 interaction</article-title><source>J. Mol. Struct.</source><year>2023</year><volume>1289</volume><fpage>135900</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2023.135900</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Geng, Q. et al. Synthesis and peliminary ealuation of ainophenol drivatives as mlecular glues bocking PD-1/PD-L1 interaction. <italic toggle="yes">J. Mol. Struct.</italic><bold>1289</bold>, 135900 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uesato</surname><given-names>S</given-names></name><etal/></person-group><article-title>Discovery of new low-molecular-weight p53-mdmx disruptors and their anti-cancer activities</article-title><source>Bioorg. Med. Chem.</source><year>2016</year><volume>24</volume><fpage>1919</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.03.021</pub-id><pub-id pub-id-type="pmid">27010502</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Uesato, S. et al. Discovery of new low-molecular-weight p53-mdmx disruptors and their anti-cancer activities. <italic toggle="yes">Bioorg. Med. Chem.</italic><bold>24</bold>, 1919&#8211;1926 (2016).<pub-id pub-id-type="pmid">27010502</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2016.03.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Chupak, L. S. &amp; Zheng, X. Compounds useful as immunomodulators. WO2015034820A1 (2015).</mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkona</surname><given-names>S</given-names></name><name name-style="western"><surname>Diamandis</surname><given-names>EP</given-names></name><name name-style="western"><surname>Blasutig</surname><given-names>IM</given-names></name></person-group><article-title>Cancer immunotherapy: The beginning of the end of cancer?</article-title><source>BMC Med.</source><year>2016</year><volume>14</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Farkona, S., Diamandis, E. P. &amp; Blasutig, I. M. Cancer immunotherapy: The beginning of the end of cancer?. <italic toggle="yes">BMC Med.</italic><bold>14</bold>, 73 (2016).<pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonia</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Vansteenkiste</surname><given-names>JF</given-names></name><name name-style="western"><surname>Moon</surname><given-names>E</given-names></name></person-group><article-title>Immunotherapy: Beyond anti-PD-1 and anti-PD-L1 therapies</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2016</year><volume>35</volume><fpage>e450</fpage><lpage>e458</lpage><pub-id pub-id-type="doi">10.1200/EDBK_158712</pub-id><pub-id pub-id-type="pmid">27249753</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Antonia, S. J., Vansteenkiste, J. F. &amp; Moon, E. Immunotherapy: Beyond anti-PD-1 and anti-PD-L1 therapies. <italic toggle="yes">Am. Soc. Clin. Oncol. Educ. Book</italic><bold>35</bold>, e450&#8211;e458 (2016).<pub-id pub-id-type="pmid">27249753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_158712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norde</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Coinhibitory molecules in hematologic malignancies: Targets for therapeutic intervention</article-title><source>Blood</source><year>2012</year><volume>120</volume><fpage>728</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-02-412510</pub-id><pub-id pub-id-type="pmid">22563087</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Norde, W. J. et al. Coinhibitory molecules in hematologic malignancies: Targets for therapeutic intervention. <italic toggle="yes">Blood</italic><bold>120</bold>, 728&#8211;736 (2012).<pub-id pub-id-type="pmid">22563087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2012-02-412510</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells</article-title><source>Carcinogenesis</source><year>2019</year><volume>40</volume><fpage>1132</fpage><lpage>1141</lpage><pub-id pub-id-type="pmid">30715244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgz017</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhao, Y. et al. Depression promotes hepatocellular carcinoma progression through a glucocorticoid-mediated upregulation of PD-1 expression in tumor-infiltrating NK cells. <italic toggle="yes">Carcinogenesis</italic><bold>40</bold>, 1132&#8211;1141 (2019).<pub-id pub-id-type="pmid">30715244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/carcin/bgz017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>2090</fpage><lpage>2098</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.02.055</pub-id><pub-id pub-id-type="pmid">30837171</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Zhang, H. et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. <italic toggle="yes">Vaccine</italic><bold>37</bold>, 2090&#8211;2098 (2019).<pub-id pub-id-type="pmid">30837171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.02.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghiotto</surname><given-names>M</given-names></name><etal/></person-group><article-title>PD-L1 and PD-L2 Differ in their molecular mechanisms of interaction with PD-1</article-title><source>Int. Immunol.</source><year>2010</year><volume>22</volume><fpage>651</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxq049</pub-id><pub-id pub-id-type="pmid">20587542</pub-id><pub-id pub-id-type="pmcid">PMC3168865</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Ghiotto, M. et al. PD-L1 and PD-L2 Differ in their molecular mechanisms of interaction with PD-1. <italic toggle="yes">Int. Immunol.</italic><bold>22</bold>, 651&#8211;660 (2010).<pub-id pub-id-type="pmid">20587542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxq049</pub-id><pub-id pub-id-type="pmcid">PMC3168865</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascolutti</surname><given-names>R</given-names></name><etal/></person-group><article-title>Structure and dynamics of PD-L1 and an ultra-high-affinity PD-1 receptor mutant</article-title><source>Structure</source><year>2016</year><volume>24</volume><fpage>1719</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.06.026</pub-id><pub-id pub-id-type="pmid">27618663</pub-id><pub-id pub-id-type="pmcid">PMC5052120</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Pascolutti, R. et al. Structure and dynamics of PD-L1 and an ultra-high-affinity PD-1 receptor mutant. <italic toggle="yes">Structure</italic><bold>24</bold>, 1719&#8211;1728 (2016).<pub-id pub-id-type="pmid">27618663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.str.2016.06.026</pub-id><pub-id pub-id-type="pmcid">PMC5052120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comprehensive in vitro characterization of PD-L1 small molecule inhibitors</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>12392</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-48826-6</pub-id><pub-id pub-id-type="pmid">31455818</pub-id><pub-id pub-id-type="pmcid">PMC6712002</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Ganesan, A. et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. <italic toggle="yes">Sci. Rep.</italic><bold>9</bold>, 12392 (2019).<pub-id pub-id-type="pmid">31455818</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-019-48826-6</pub-id><pub-id pub-id-type="pmcid">PMC6712002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veljkovi&#263;</surname><given-names>IS</given-names></name><etal/></person-group><article-title>What is the preferred geometry of sulfur&#8211;disulfide interactions?</article-title><source>CrystEngComm</source><year>2020</year><volume>22</volume><fpage>7262</fpage><lpage>7271</lpage><pub-id pub-id-type="doi">10.1039/D0CE00211A</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Veljkovi&#263;, I. S. et al. What is the preferred geometry of sulfur&#8211;disulfide interactions?. <italic toggle="yes">CrystEngComm</italic><bold>22</bold>, 7262&#8211;7271 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Breakthrough infections elicit potent, broad, and durable neutralizing antibody responses</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>872</fpage><lpage>880.E3</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.011</pub-id><pub-id pub-id-type="pmid">35123650</pub-id><pub-id pub-id-type="pmcid">PMC8769922</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Walls, A. C. et al. SARS-CoV-2 Breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <italic toggle="yes">Cell</italic><bold>185</bold>, 872-880.E3 (2022).<pub-id pub-id-type="pmid">35123650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2022.01.011</pub-id><pub-id pub-id-type="pmcid">PMC8769922</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsurudome</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: A Phase II, open-label, uncontrolled trial in Japan</article-title><source>Microbiol. Immunol.</source><year>2015</year><volume>59</volume><fpage>597</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12316</pub-id><pub-id pub-id-type="pmid">26272602</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Tsurudome, Y. et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: A Phase II, open-label, uncontrolled trial in Japan. <italic toggle="yes">Microbiol. Immunol.</italic><bold>59</bold>, 597&#8211;604 (2015).<pub-id pub-id-type="pmid">26272602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1348-0421.12316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lienlaf</surname><given-names>M</given-names></name><etal/></person-group><article-title>Essential role of HDAC6 in the regulation of PD-L1 in melanoma</article-title><source>Mol. Oncol.</source><year>2016</year><volume>10</volume><fpage>735</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2015.12.012</pub-id><pub-id pub-id-type="pmid">26775640</pub-id><pub-id pub-id-type="pmcid">PMC4870131</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Lienlaf, M. et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. <italic toggle="yes">Mol. Oncol.</italic><bold>10</bold>, 735&#8211;750 (2016).<pub-id pub-id-type="pmid">26775640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molonc.2015.12.012</pub-id><pub-id pub-id-type="pmcid">PMC4870131</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatto</surname><given-names>L</given-names></name><etal/></person-group><article-title>Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19</article-title><source>Immunotherapy</source><year>2020</year><volume>12</volume><fpage>1111</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.2217/imt-2020-0109</pub-id><pub-id pub-id-type="pmid">32594820</pub-id><pub-id pub-id-type="pmcid">PMC7325496</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Gatto, L. et al. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19. <italic toggle="yes">Immunotherapy</italic><bold>12</bold>, 1111&#8211;1114 (2020).<pub-id pub-id-type="pmid">32594820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt-2020-0109</pub-id><pub-id pub-id-type="pmcid">PMC7325496</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cosimo</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibitors: A physiology-driven approach to the treatment of coronavirus disease 2019</article-title><source>Eur. J. Cancer</source><year>2020</year><volume>135</volume><fpage>62</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2020.05.026</pub-id><pub-id pub-id-type="pmid">32544799</pub-id><pub-id pub-id-type="pmcid">PMC7269953</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Cosimo, S. D. et al. Immune checkpoint inhibitors: A physiology-driven approach to the treatment of coronavirus disease 2019. <italic toggle="yes">Eur. J. Cancer</italic><bold>135</bold>, 62&#8211;65 (2020).<pub-id pub-id-type="pmid">32544799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2020.05.026</pub-id><pub-id pub-id-type="pmcid">PMC7269953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambichler</surname><given-names>T</given-names></name><etal/></person-group><article-title>On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19</article-title><source>J. Immunother. Cancer</source><year>2020</year><volume>8</volume><fpage>e001145</fpage><pub-id pub-id-type="doi">10.1136/jitc-2020-001145</pub-id><pub-id pub-id-type="pmid">32611687</pub-id><pub-id pub-id-type="pmcid">PMC7358098</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Gambichler, T. et al. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. <italic toggle="yes">J. Immunother. Cancer</italic><bold>8</bold>, e001145 (2020).<pub-id pub-id-type="pmid">32611687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2020-001145</pub-id><pub-id pub-id-type="pmcid">PMC7358098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garner</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Disposition and metabolism of 2&#8217;, 2&#8217;-dithiobisbenzanilide in rodents following intravenous and oral administration and dermal application</article-title><source>Toxicol. Rep.</source><year>2020</year><volume>7</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2020.07.006</pub-id><pub-id pub-id-type="pmid">32760656</pub-id><pub-id pub-id-type="pmcid">PMC7390853</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Garner, C. E. et al. Disposition and metabolism of 2&#8217;, 2&#8217;-dithiobisbenzanilide in rodents following intravenous and oral administration and dermal application. <italic toggle="yes">Toxicol. Rep.</italic><bold>7</bold>, 883&#8211;892 (2020).<pub-id pub-id-type="pmid">32760656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxrep.2020.07.006</pub-id><pub-id pub-id-type="pmcid">PMC7390853</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name></person-group><article-title>Study on the effect of tire and road wear particles on the environment and human health</article-title><source>J. Mater. Cycles Waste Manage.</source><year>2022</year><volume>33</volume><fpage>386</fpage><lpage>391</lpage></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Shibata, T. Study on the effect of tire and road wear particles on the environment and human health. <italic toggle="yes">J. Mater. Cycles Waste Manage.</italic><bold>33</bold>, 386&#8211;391 (2022).</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maji</surname><given-names>UJ</given-names></name><etal/></person-group><article-title>Toxicological effects of tire rubber-derived 6PPD-quinone, a species-specific toxicant, and dithiobisbenzanilide (DTBBA) in the marine rotifer <italic toggle="yes">Brachionus koreanus</italic></article-title><source>Mar. Pollut. Bull.</source><year>2023</year><volume>192</volume><fpage>115002</fpage><pub-id pub-id-type="doi">10.1016/j.marpolbul.2023.115002</pub-id><pub-id pub-id-type="pmid">37182240</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Maji, U. J. et al. Toxicological effects of tire rubber-derived 6PPD-quinone, a species-specific toxicant, and dithiobisbenzanilide (DTBBA) in the marine rotifer <italic toggle="yes">Brachionus koreanus</italic>. <italic toggle="yes">Mar. Pollut. Bull.</italic><bold>192</bold>, 115002 (2023).<pub-id pub-id-type="pmid">37182240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.marpolbul.2023.115002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreider</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Physical and chemical characterization of tire-related particles: Comparison of particles generated using different methodologies</article-title><source>Sci. Total Environ.</source><year>2010</year><volume>408</volume><fpage>652</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2009.10.016</pub-id><pub-id pub-id-type="pmid">19896165</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Kreider, M. L. et al. Physical and chemical characterization of tire-related particles: Comparison of particles generated using different methodologies. <italic toggle="yes">Sci. Total Environ.</italic><bold>408</bold>, 652&#8211;659 (2010).<pub-id pub-id-type="pmid">19896165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scitotenv.2009.10.016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unice</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kreider</surname><given-names>ML</given-names></name><name name-style="western"><surname>Panko</surname><given-names>JM</given-names></name></person-group><article-title>Comparison of tire and road wear particle concentrations in sediment for watersheds in France, Japan, and the United States by quantitative pyrolysis GC/MS analysis</article-title><source>Environ. Sci. Technol.</source><year>2013</year><volume>47</volume><fpage>9223</fpage><lpage>9231</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/es400871j</pub-id><pub-id pub-id-type="pmid">23841521</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Unice, K. M., Kreider, M. L. &amp; Panko, J. M. Comparison of tire and road wear particle concentrations in sediment for watersheds in France, Japan, and the United States by quantitative pyrolysis GC/MS analysis. <italic toggle="yes">Environ. Sci. Technol.</italic><bold>47</bold>, 9223&#8211;9231 (2013).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/es400871j</pub-id><pub-id pub-id-type="pmid">23841521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>NM</given-names></name></person-group><article-title>A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin</article-title><source>Biochem. J.</source><year>1965</year><volume>94</volume><fpage>23C</fpage><lpage>24C</lpage><pub-id pub-id-type="doi">10.1042/bj0940023C</pub-id><pub-id pub-id-type="pmid">14340040</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Green, N. M. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. <italic toggle="yes">Biochem. J.</italic><bold>94</bold>, 23C-24C (1965).<pub-id pub-id-type="pmid">14340040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/bj0940023c</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohta</surname><given-names>Y</given-names></name><etal/></person-group><article-title>In vivo anti-influenza virus activity of an immunomodulatory acidic polysaccharide isolated from <italic toggle="yes">Cordyceps militaris</italic> grown on germinated soybeans</article-title><source>J. Agric. Food Chem.</source><year>2007</year><volume>55</volume><fpage>10194</fpage><lpage>10199</lpage><pub-id pub-id-type="doi">10.1021/jf0721287</pub-id><pub-id pub-id-type="pmid">17988090</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Ohta, Y. et al. In vivo anti-influenza virus activity of an immunomodulatory acidic polysaccharide isolated from <italic toggle="yes">Cordyceps militaris</italic> grown on germinated soybeans. <italic toggle="yes">J. Agric. Food Chem.</italic><bold>55</bold>, 10194&#8211;10199 (2007).<pub-id pub-id-type="pmid">17988090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jf0721287</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>